Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Emergent BioSolutions excels in Q3, poised for growth opportunities

Emergent BioSolutions delivered a strong Q3 performance, showcasing financial resilience, operational excellence, and strategic advancements across key business segments.
While facing challenges in pricing dynamics and revenue mix, the company's focus on growth opportunities, compliance, and leadership appointments positions them for sustained success.
With a solid financial foundation, improved guidance, and a strategic roadmap for growth, Emergent is well-equipped to navigate challenges, capitalize on opportunities, and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The IBD SmartSelect Composite Rating for Emergent Biosolutions rose from 94 to 99 Monday. 
The post Composite Rating For Emergent Biosolutions Rises To 99 appeared first on Investor's Business Daily.

Composite Rating For Emergent Biosolutions Rises To 99

The expert in bioterrorism and emerging infectious diseases had a great second quarter, with more to come.

Here's Why Emergent BioSolutions Stock Jumped Today

Emergent BioSolutions, Inc. (EBS) CEO Bob Kramer on Q2 2020 Results - Earnings Call Transcript

GAITHERSBURG, Md., July  30, 2020  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and six months ended June 30, 2020 and revised upward full year 2020 guidance.

Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance

AstraZeneca

BioNTech SE

Catalent

Johnson & Johnson

Lonza Group AG

Moderna

Novavax

Pfizer

The Race To Erase COVID-19

There could be an even larger contract coming if the vaccine to prevent COVID-19 is successful.

Emergent BioSolutions Triples Its Coronavirus-Vaccine Manufacturing Contract With AstraZeneca

GAITHERSBURG, Md., July  27, 2020  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222. The agreement is valued at approximately $174 million through 2021 and follows an $87 million contract in June for development services, performance and process qualification, raw materials and an initial capacity reservation.

Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate

Emergent’s contract manufacturing capabilities make it a much-desired collaborator in the race for a coronavirus vaccine.

Should Emergent Biosolutions Be Your Next Coronavirus Buy?

During Emergent's (EBS) upcoming Q2 earnings conference, investors will focus on the company's CDMO collaborations to help partners manufacture a vaccine against COVID-19.

Emergent (EBS) to Report Q2 Earnings: What's in the Cards?

GAITHERSBURG, Md., July  21, 2020  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Standard & Poor’s (S&P) has indicated that the company will be added to the S&P MidCap 400® index, effective prior to the open of trading on Friday, July 24. The company will be classified under S&P’s Global Industry Classification Standard (GICS) Biotechnology Sub-Industry index.

Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index

Emergent Biosolutions (EBS) possesses solid growth attributes, which could help it handily outperform the market.

Is Emergent Biosolutions (EBS) a Solid Growth Stock? 3 Reasons to Think " Yes "

NEW YORK, July 20, 2020 /PRNewswire/ -- S&P SmallCap 600 constituent Emergent BioSolutions Inc. (NYSE: EBS) will replace Caesars Entertainment Corp.

Emergent BioSolutions Set to Join S&P MidCap 400; First Hawaiian to Join S&P SmallCap 600

Does Emergent Biosolutions (EBS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Emergent Biosolutions (EBS) is a Great Momentum Stock to Buy

GAITHERSBURG, Md., July  16, 2020  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2020, recent business developments, revenue guidance for the third quarter of 2020, and financial outlook for full year 2020.

Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020

Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.

Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals

NEW YORK and GAITHERSBURG, Md. and NEW ORLEANS and LAFAYETTE, La., July  08, 2020  (GLOBE NEWSWIRE) -- The Mount Sinai Health System, Emergent BioSolutions (NYSE: EBS), and ImmunoTek Bio Centers today announced that they will collaborate to develop, manufacture, and conduct clinical trials to evaluate Emergent’s COVID-19 hyperimmune globulin product, COVID-HIG, including a post-exposure prophylaxis (PEP) study on health care providers at high risk of COVID-19 infection and other high-risk populations, with $34.6 million in funding from the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

AbbVie

Channeladvisor

Pilgrim's Pride

Boston Beer Company

Zoom Video

The current health scare drives market volatility and calls for investment in consumer staples, healthcare and IT sectors for stable returns.

6 Stocks to Wade Through the Spike in Coronavirus Cases

As of late, it has definitely been a great time to be an investor in Emergent BioSolutions

Will Emergent BioSolutions' Shares March Higher, Can It Continue?

Shares of Emergent BioSolutions Inc. EBS, +2.64% were up 1.1% in premarket trading on Monday after it announced a five-year deal with Johnson & Johnson JNJ, +0.42% to manufacture the drug substance for the drugmaker's still-investigational COVID-19 vaccine.

Emergent BioSolutions inks coronavirus vaccine manufacturing deal with J&J

Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.

Emergent to make drug substance for J&J's COVID-19 vaccine candidate

GAITHERSBURG, Md., July  06, 2020  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.

Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate   

Regeneron Pharmaceuticals

Both of these companies could play a huge role in ending the COVID-19 pandemic.

Better Coronavirus Stock: Emergent Biosolutions vs. Regeneron

This biotech has emerged as the manufacturing partner of choice for companies developing COVID-19 vaccines.

Why Emergent BioSolutions Stock Soared 47% in the First Half of 2020

Exelixis

Genmab - ADR

Vertex Pharmaceuticals

These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.

5 Booming Biotech Stocks to Buy

Emergent BioSolutions has become the go-to manufacturing partner for companies looking to develop vaccines for the coronavirus.

News for Emergent BioSolutions Stock (EBS)